Opinion|Videos|February 14, 2025
Reflections on 2024’s Progress in R/R CLL
Panelists discuss how the relapsed/refractory chronic lymphocytic leukemia treatment landscape evolved significantly in 2024 with expanded Bruton tyrosine kinase inhibitor options, growing real-world evidence for newer agents, and emerging combination strategies, while expressing optimism for future advances in personalized therapy approaches and novel drug development.
Advertisement
Episodes in this series
Advertisement
Related Content
Advertisement
Advertisement
Advertisement
Trending on AJMC
1
FDA Approves Moderna’s mRNA Flu Vaccine After Phase 3 Success
2
OneOncology Partners With OpenEvidence to Give Physicians Access Within Clinical Workflows
3
High-Dose Vitamin D3 Fails to Improve PFS in Phase 3 Metastatic CRC Trial
4
Patients With MASLD Had More Than 2 Times Higher Odds of Eosinophilic Esophagitis Across Age Groups
5